Breast cancer therapeutics include hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. Breast cancer is the most common type of invasive cancer affecting women, and it is the most common cause of cancer death among women worldwide. It usually originates from the inner lining of milk ducts or lobules responsible for supplying the milk. The malignant type of tumor can spread to other cells present in the body. North America dominates market share for breast cancer therapeutics considering highest prevalence rate, modern medical technologies, health insurance coverage, and optimum per capita income.
The global breast cancer therapeutics market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug classes – brand name (chemical name) such as antimetabolites – Gemzar (gemcitabine), aromatase inhibitors – Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors – Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors – Fareston, Faslodex, Zoladex; and Mitotic inhibitors – Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% – 2017 to 2021).
The global breast cancer therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global breast cancer therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global breast cancer therapeutics market and included in this report are AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., Teva Pharmaceutical Industries Ltd.